HIV Vaccine Rationale, Design and Testing

Title: HIV Vaccine Rationale, Design and Testing

Volume: 3 Issue: 2

Author(s): Robert E. Sealy, Julia L. Hurwitz, Louis N. Martin, James L. Blanchard, Peter C. Doherty, Pamela J. Freiden, Timothy D. Lockey, Brita Brown, John Stambas, Karen S. Slobod, Bart G. Jones, Amy Zirkel, Sherri Surman, Xiaoyan Zhan, Scott A. Brown, Mattia Bonsignori and Chris Coleclough

Affiliation:

Keywords: hiv envelope protein, cocktail, breadth

Abstract: A central obstacle to the design of a global HIV vaccine is viral diversity. Antigenic differences in envelope proteins result in distinct HIV serotypes, operationally defined such that antibodies raised against envelope molecules from one serotype will not bind envelope molecules from a different serotype. The existence of serotypes has presented a similar challenge to vaccine development against other pathogens. In such cases, antigenic diversity has been addressed by vaccine design. For example, the poliovirus vaccine includes three serotypes of poliovirus, and Pneumovax(ρ) presents a cocktail of 23 pneumococcal variants to the immune system. It is likely that a successful vaccine for HIV must also comprise a cocktail of antigens. Here, data relevant to the development of cocktail vaccines, designed to harness diverse, envelope-specific Bcell and T-cell responses, are reviewed.

Cite this article as:

Sealy E. Robert, L. Hurwitz Julia, N. Martin Louis, L. Blanchard James, C. Doherty Peter, J. Freiden Pamela, D. Lockey Timothy, Brown Brita, Stambas John, Slobod S. Karen, Jones G. Bart, Zirkel Amy, Surman Sherri, Zhan Xiaoyan, Brown A. Scott, Bonsignori Mattia and Coleclough Chris, HIV Vaccine Rationale, Design and Testing, Current HIV Research 2005; 3 (2) . https://dx.doi.org/10.2174/1570162053506928